Results 241 to 250 of about 8,117 (271)

Overcoming Barriers to Remission in Severe Eosinophilic Asthma: Two‐Year Real‐World Data With Benralizumab

Clinical and Experimental Allergy
Benralizumab has been reported to lead to clinical remission of severe eosinophilic asthma (SEA) at 1 year in some patients. However, whether this is maintained over a longer term remains unclear.
D. J. Jackson, Hassan Burhan, H. Rupani, Paul E. Pfeffer, I. Clifton, Shoaib Faruqi, J. Dhariwal, P. Patel, T. Morris, Joe Lipworth, Michael Watt, C. Lupton, S. Dube, J. Hickey, A. Nanzer   +14 more
semanticscholar   +1 more source

Comparative Effectiveness of Mepolizumab, Benralizumab and Dupilumab among Patients with Difficult-to-Control Asthma.

Annals of the American Thoracic Society
Rationale The comparative effectiveness of biologics used as add-on therapy in the management of difficult-to-control asthma is unclear. Objective To compare the effectiveness of dupilumab, mepolizumab and benralizumab among patients with difficult-to ...
C. Kearney, Ruchika Sangani, Divya A. Shankar, George T O'Connor, A. Law, A. Walkey, N. Bosch   +6 more
semanticscholar   +1 more source

Real-world effectiveness of dupilumab versus benralizumab and mepolizumab.

Allergy and Asthma Proceedings
INTRODUCTION In the United States, this real-world study compared the effectiveness of dupilumab, benralizumab, andmepolizumab in reducing exacerbations and systemic corticosteroid (SCS) prescriptions among patients with asthma.
Eugene Bleecker, M. Blaiss, J. Jacob-Nara, L. Huynh, Tracy Guo, Mingchen Ye, R. Stanford, Zhixiao Wang, X. Soler, Arpita Nag, Radhika Nair, K. Borsos   +11 more
semanticscholar   +1 more source

Benralizumab treatment and SARP cluster analysis

Airway pharmacology and treatment, 2019
Background: Severe asthma is heterogeneous, with different phenotypes and endotypes. Aims and Objectives: We identified subsets of benralizumab-treated patients (pts) with severe asthma by assignment to Severe Asthma Research Program (SARP) clinical clusters. Methods: Pts (N=2,281) from SIROCCO (Lancet 2016:2115; n=1,082) and CALIMA (Lancet 2016:2128;
Huashi Li, James Zangrilli, Mitchell Goldman, Deborah A. Meyers, Ian Hirsch, Xingnan Li, Paul Newbold, Eugene R. Bleecker   +7 more
openaire   +2 more sources

Benralizumab in eosinophilic granulomatosis with polyangiitis

Medicina Clínica, 2022
Daniel Laorden, David Romero, Javier Domínguez Ortega   +2 more
openaire   +3 more sources

Successful Benralizumab treatment in acute near-fatal asthma with ECMO support: a case report

Journal of Asthma
Introduction Near-fatal asthma (NFA) is a severe condition that can lead to respiratory arrest or high carbon dioxide levels, often requiring mechanical ventilation.
Francesca Montagnolo, Salvatore Grasso, Lidia Dalfino, Andrea Portacci, Francesca Romana Viterbo, V. Quaranta, G. E. Carpagnano   +6 more
semanticscholar   +1 more source

Glucocorticoid Sparing of Benralizumab in Asthma

New England Journal of Medicine, 2017
Xiaoping Huang, Xue Kong, Chao Cao
openaire   +4 more sources

Benralizumab: from tissue distribution to eosinophilic cytotoxicity up to potential immunoregulation

Expert Opinion on Biological Therapy
Introduction Benralizumab, a monoclonal IgG antibody, has emerged as a key therapeutic agent in severe asthma by specifically targeting eosinophils, pivotal cells that drive inflammation and tissue damage.
A. Vultaggio, L. Bergantini, C. Crimi, Andrea Matucci, F. Menzella, J. Schroeder, G. Senna, P. Cameli   +7 more
semanticscholar   +1 more source

Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double‐blind placebo‐controlled trial

Clinical and Experimental Allergy, 2021
Andrew P Lane, Antoine E Azar, Jody Tversky   +2 more
exaly  

Successful treatment of Kimura disease with benralizumab

Annals of Hematology, 2022
Vivian G. Szeto, Benjamin Chin-Yee, Mina Dehghani, Kamilia Rizkalla, Christopher Licskai, Cyrus C. Hsia   +5 more
openaire   +2 more sources